Drugs / Maytenus senegalensis
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04944966 | Jun 2021 → Sep 2022 | malaria | Ifakara Health Institute | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Maytenus senegalensis | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04944966 ↗ |
| Known as | Malherbal | “* Maytenus senegalensis (Malherbal) has a very long history of safe medicinal use in Africa in adult as well as infants and children.” NCT04944966 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “The herbal medicine (Maytenus senegalensis) has been scientifically investigated for acute toxicity in vitro and antiplasmodial activity both in vitro and in vivo where it...” NCT04944966 ↗ |
| Route | Oral | “It will be administered orally at a dose of 800mg 8 hourly for 4 days.” NCT04944966 ↗ |